---
title: Hematology/Oncology
icon: fontawesome/solid/biohazard
author: J. Austin Straley, DO
date: 2024-03-16
permalink: /heme-onc
categories:
    - Hematology
    - Oncology
---

## Hematology

- Anemia
    - Anemia of Chronic Disease
        - [Advancements in anemias related to chronic conditions][1]
    - Transfusion thresholds
        - [TRICC: Better survival in critically ill with Hgb target of >7 than >10][3]
        - [TRISS: Similar mortality with Hgb target of >7 than >9 in septic shock][4]
- Breast Cancer
    - [ATLAS: In ER+ BC, tamoxifen for 10 years reduced recurrence/mortality, increased endometrial cancer and PE risk][5]
- Chronic Leukemia
    - CLL
        - [Ibrutinib-Rituximab > FCR if <70 y/o and untreated][6]
    - CML
        - [IRIS: Imantinib > IFNa/cytarabine in delaying disease progression][7]
- DIC
- General
    - [Multiple CTs increase risk of leukemia and brain tumors][2]
- Iron Deficiency Anemia
    - [Consensus Statement on Peri-operative management of Anemia and IDA][8]
    - [IRONMAN: IV Iron not better than placebo, did not change # of pRBC transfusion during stay][9]
- Lymphomas
- Thrombocytopenia
    - [EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact][10]
    - [Drug-induced thrombocytopenia][11]
        - [PubMed][12]
- VTE
    - [SOME: Not better to screen for occult malignancy in first unprovoked VTE][13]
    - [AMPLIFY: Oral Apixaban for the Treatment of Acute VTE][14]
    - PE
        - [Causes of Elevated D-Dimer][15]
        - [ADJUST-PE: Age-adjusted D-Dimer (Age x 10) in patients >50 r/o more pts][16]
        - [ERC/PROPER: Low suspicion and PERC(-) reduces VTE probability to <2%][17]
            - [Also][20]
        - [PIOPED II: CTA is sensitive (90%) and specific (95%) for PE][18]
    - DVT
        - Wells DVT Criteria
            - [Rule-Out with Negative D-Dimer][19]
            - [Diagnosis/Treatment][21]
            - [Treatment][23]
        - CLOT: Dalteparin > Warfarin in preventing recurrent VTE of malignancy

## Oncology

- Breast Cancer
- Chemotherapy
    - General
        - Increased risk of MDS, Mixed MDS/MPN, and AML (10-20% of all cases of these cancers are chemotherapy related)
            - [Therapy-Related Myeloid Leukemia][22]
            - [Etiology and management of therapy-related myeloid leukemia][24]
    - Common Regimens
        - ABVD
            - Adriamycin, Bleomycin, Vinblastine, Dacarbazine
            - Hodgkin Lymphoma
        - BEACOPP
            - Bleomycin, Etoposide, Adriamycin/doxorubicin, Cyclophosphamide, Oncovorin/vincristine, Procarbazine, Prednisone
            - Hodgkin Lymphoma
        - FOLFIRI
            - Leucovorin, 5-Fluorouracil, Irinotecan
            - Advanced-stage and Metastatic Colorectal Cancer
        - FOLFOX
            - Leucovorin, 5-Fluorouracil, Oxaliplatin
        - R-CHOP
            - Rituximab, Cyclophosphamide, Hydroxy-doxorubicin, Oncovorin/Vincristine, Prednisone

[1]: https://pubmed.ncbi.nlm.nih.gov/20618092/{:target="_blank"}
[2]: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60815-0/fulltext/{:target="_blank"}
[3]: https://pubmed.ncbi.nlm.nih.gov/9971864/{:target="_blank"}
[4]: https://pubmed.ncbi.nlm.nih.gov/25270275/{:target="_blank"}
[5]: https://pubmed.ncbi.nlm.nih.gov/23219286/{:target="_blank"}
[6]: https://pubmed.ncbi.nlm.nih.gov/31365801/{:target="_blank"}
[7]: https://pubmed.ncbi.nlm.nih.gov/12637609/{:target="_blank"}
[8]: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.13773/{:target="_blank"}
[9]: https://pubmed.ncbi.nlm.nih.gov/27686346/{:target="_blank"}
[10]: https://pubmed.ncbi.nlm.nih.gov/22868791/{:target="_blank"}
[11]: https://pubmed.ncbi.nlm.nih.gov/20008194/{:target="_blank"}
[12]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413903/{:target="_blank"}
[13]: https://www.nejm.org/doi/full/10.1056/NEJMoa1506623/{:target="_blank"}
[14]: https://www.nejm.org/doi/full/10.1056/NEJMoa1302507/{:target="_blank"}
[15]: https://www.njmonline.nl/article_ft.php?a=1790&d=1189&i=201{:target="_blank"}
[16]: https://pubmed.ncbi.nlm.nih.gov/24643601/{:target="_blank"}
[17]: https://pubmed.ncbi.nlm.nih.gov/18318689/{:target="_blank"}
[18]: https://pubmed.ncbi.nlm.nih.gov/16738268/{:target="_blank"}
[19]: https://www.nejm.org/doi/full/10.1056/NEJMoa023153/{:target="_blank"}
[20]: https://pubmed.ncbi.nlm.nih.gov/29450523/{:target="_blank"}
[21]: https://pubmed.ncbi.nlm.nih.gov/17060659/{:target="_blank"}
[22]: https://pubmed.ncbi.nlm.nih.gov/18692692/{:target="_blank"}
[23]: https://pubmed.ncbi.nlm.nih.gov/22315257/{:target="_blank"}
[24]: https://pubmed.ncbi.nlm.nih.gov/18024664/{:target="_blank"}
